ABIOMED Inc. (ABMD)

384.88
NASDAQ : Health Technology
Prev Close 381.98
Day Low/High 380.97 / 386.72
52 Wk Low/High 158.71 / 450.93
Avg Volume 601.80K
Exchange NASDAQ
Shares Outstanding 44.88M
Market Cap 17.14B
EPS 2.50
P/E Ratio 106.70
Div & Yield N.A. (N.A)

Latest News

10 Stocks That Investors Have Plowed Into This Year With Reckless Abandon

10 Stocks That Investors Have Plowed Into This Year With Reckless Abandon

Investors have fallen in love with 10 stocks this year despite their heady valuations. Talk about dangerous.

Automatic Data Processing, ADT, Abiomed: 'Mad Money' Lightning Round

Automatic Data Processing, ADT, Abiomed: 'Mad Money' Lightning Round

Jim Cramer weighs in on Automatic Data Processing, ADT, Discovery Communications, Abiomed, L Brands and more.

Stocks Defying Gravity: Cramer's 'Mad Money' Recap (Monday 6/11/18)

Stocks Defying Gravity: Cramer's 'Mad Money' Recap (Monday 6/11/18)

Markets look calm, but we're seeing some extraordinary breakouts, says Jim Cramer.

FANG Stocks Only Outperform in Odd Years: Here Are 18 Alternative Picks for 2018

FANG Stocks Only Outperform in Odd Years: Here Are 18 Alternative Picks for 2018

For the past 11 years, FANG stocks have outperformed in years that end in an odd number and underperformed in years that end with an even number. That's not good news moving into 2018.

Closing the Door on Abiomed

Closing the Door on Abiomed

It's good as a long-term name, but as an options trade, it's time to go.

Capturing Profits on AIG

Capturing Profits on AIG

Let's roll with the sure thing and not wait for expiry.

A Roundup of My Open Positions

A Roundup of My Open Positions

Update on the last few Action Alerts Options trades.

Pumped Up About Abiomed Collar Play

Pumped Up About Abiomed Collar Play

The producer of heart pumps also is an interesting name for the longer term.

Abiomed Announces Q1 FY 2018 Revenue Of $132.5 Million, Up 29% Over Prior Year

Abiomed Announces Q1 FY 2018 Revenue Of $132.5 Million, Up 29% Over Prior Year

Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance

TheStreet Quant Rating: B (Buy)